Accro Bioscience, a pioneering clinical-stage biotech company with an unwavering commitment to understanding the molecular mechanisms of regulated cell death and its associated pathogenesis in human diseases, is thrilled to announce the successful closing of an 18-million-dollar funding round. This substantial investment marks a significant milestone for the company, reflecting strong investor confidence in its innovative approach and valuable contributions to biomedical research. With a research pipeline focused on deciphering the intricate cellular processes that drive disease progression, Accro Bioscience is uniquely positioned to transform scientific insights into transformative therapies. The new funding will predominantly be allocated to enhancing preclinical research, accelerating clinical trials, and expanding the company’s state-of-the-art laboratory facilities. Additionally, it will support the recruitment of top-tier talent in both research and development, ensuring that the company continues to push the boundaries of scientific discovery and innovation. As Accro Bioscience embarks on the next phase of its journey, the funds will empower the organization to explore novel therapeutic targets and refine its strategies to combat diseases at their root causes. This investment not only bolsters the company’s pursuit of cutting-edge treatments but also underscores the broader industry and investor dedication to fostering groundbreaking advancements in healthcare. By merging robust scientific inquiry with strategic financial backing, Accro Bioscience is set to drive progress in the field of regulated cell death research, ultimately offering hope to patients worldwide who suffer from conditions that remain unmet by current treatments.
Accropeutics Raises $18 Million in Series B Funding to Accelerate Accro Bioscience’s Regulated Cell Death Research Breakthroughs
Recently funded · $18.0M Series bPharmaceuticals
Get the full Accropeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
